Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Mitiglinide - Kissei Pharmaceutical

Drug Profile

Mitiglinide - Kissei Pharmaceutical

Alternative Names: Glinsuna; Glufast; KAD-1229; Kuai ruo tuo; S 21403

Latest Information Update: 06 Aug 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Kissei Pharmaceutical
  • Developer Aichi Gakuin University; Eisai Co Ltd; Elixir Pharmaceuticals; Hikma Pharmaceuticals; JW Pharmaceutical; Kissei Pharmaceutical; Orient Europharma; Takeda; USV
  • Class Amides; Antihyperglycaemics; Butyric acids; Isoindoles; Small molecules
  • Mechanism of Action Insulinotropin agonists; Peroxisome proliferator-activated receptor gamma agonists; Potassium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Type 2 diabetes mellitus

Most Recent Events

  • 06 Aug 2019 Launched for Type 2 diabetes mellitus in Taiwan before August 2019 (PO)
  • 06 Aug 2019 Preregistration for Type 2 diabetes mellitus in Vietnam (PO) before August 2019 (Kissei Pharmaceutical pipeline August 2019)
  • 06 Aug 2019 Registered for Type 2 diabetes mellitus in Laos (PO) before August 2019 (Kissei Pharmaceutical pipeline August 2019)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top